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(57) ABSTRACT 
The present invention relates to methods of treatment of a 
disease or pathology of the central nervous system, an eating 
disorder, or substance use disorder, drug dependence/abuse 
and withdrawal therefrom comprising administering at least 
one N-phenylalkyl amphetamine derivative and pharmaceu-
tical compositions comprising at least one N-phenylalkyl 
amphetamine derivative to an individual in need thereof. 
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1 
VESICULAR MONOAMINE 
TRANSPORTER-2 LIGANDS AND THEIR 
USE IN THE TREATMENT OF 
PSYCHOSTIMULANT ABUSE 
FIELD OF THE INVENTION 
The present invention relates to methods treatment of a 
disease or pathology of the central nervous system, an eating 
disorder, or substance use disorder, drug dependence/abuse 
and withdrawal therefrom comprising administering N-phe-
nylalkyl amphetamine derivatives and pharmaceutical com-
positions containing these compounds to an individual in 
need thereof. 
BACKGROUND OF THE INVENTION 
2 
carboxylate; isopropylcarboxylate; carboxaldehyde; 
acetoxy; propionyloxy; isopropionyloxy; cyano; aminom-
ethyl; N-methylaminomethyl; N,N-dimethylaminomethyl; 
carboxamide; N-methylcarboxamide; N,N-dimethylcarbox-
5 amide; acetyl; propionyl; formyl; benzoyl sulfate; phenyl; 
methylsulfate; hydroxyl; methoxy; ethoxy; propoxy; iso-
propoxy; thiol; methylthio; ethylthio; propiothiol; fluoro; 
chloro; bromo; iodo; trifluoromethyl; vinyl; ally!; propargyl; 
nitro; carbamoyl; ureido; azido; isocyanate; thioisocyanate; 
10 hydroxylamino; nitroso; a saturated or unsaturated hydro-
carbon ring; a nitrogen containing heterocyclic moiety; an 
oxygen containing heterocyclic moiety; a sulfur containing 
heterocyclic moiety; a selenium containing heterocyclic 
moiety; a mixed heterocyclic moiety containing at least two 
15 atoms selected from the group consisting of nitrogen, oxy-
gen and sulfur; and ortho, meta or para-substituted benzene; 
R3 is a methyl, ethyl, propyl, isopropyl, hydroxymethyl, 
2-hydroxyethyl, 1-hyhydroxyethyl, methoxymethyl, 
2-methoxyethyl, 1-methoxyethyl, aminomethyl, 2-amino-
The action of many therapeutic neuropharmacological 
agents involve the modulation of dopamine (DA), norepi-
nephrine (NE) and serotonin (5-HT) release, uptake and 
storage within their respective terminals in the central ner-
vous system (CNS). Most neurotransmitters are stored in 
synaptic vesicles, which are prominent features of nerve 
terminals. Sequestration into vesicles appears to be respon-
sible for maintaining a ready supply of neurotransmitter 
molecules available for neuronal exocytotic release into the 
synaptic cleft. Vesicles also serve the role of protecting the 
neurotransmitter molecules from metabolic breakdown. One 
transport site on the vesicle membrane is the vesicular 
monoamine transporter-2 (VMAT2), whose role is to trans- 30 
port transmitters from the cytosol into the synaptic vesicle. 
Once the neurotransmitter is released from the terminal into 
the synaptic space, it interacts with postsynaptic receptors 
and subsequently is taken back up into the terminal via the 
plasma membrane transporter (e.g., DAT and/or the sero- 35 
tonin transporter [SERT]). Thus, transporter proteins modify 
the concentration of neurotransmitters in the cytosolic and 
vesicular storage pools, and thereby have the ability to alter 
subsequent neurotransmission. 
20 ethyl, 1-aminoethyl, N-methylaminomethyl, 2-N-methyl-
aminoethyl, 1-N-methylaminoethyl, N,N-dimethylaminom-
ethyl, 2-N,N-dimethylaminoethyl, or 1-N,N-
dimethylaminoethyl group; and 
R4 is a hydrogen atom, a methyl, ethyl, propyl, or iso-
25 propyl group. 
The compound of formula (I) may form pharmaceutically 
acceptable salts with a variety of acids. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention provides a compound of formula 
(I): 
(I) 
SUMMARY OF THE INVENTION 




m is an integer in the range from 1 to 3; 
n is zero or an integer in the range from 1 to 5; 
R1 is an aryl group which may be substituted by one or 
more substituents; 
R2 is an aryl group which may be substituted by one or 
more substituents; 
wherein substituents on R1 and R2 are independently 
selected from the group consisting of methyl; deuteromethyl 
(CD3 ); tritiomethyl (CT3 ); ethyl; propyl; isopropyl; C4 -C7 
straight chain or branched alkyl; C3 -C6 cycloalkyl; C4 -C7 
alkenyl (including cis and trans geometrical forms); benzyl; 
phenylethyl; amino; N-methylamino; N,N-dimethylamino; 
carboxylate; methylcarboxylate; ethylcarboxylate; propyl-
40 
wherein 
m is an integer in the range from 1 to 3; 
45 n is zero or an integer from 1 to 5; 
R1 and R2 are each independently an aryl group, 
wherein R1 and R2 are each independently unsubstituted 
or substituted by one or more substituents selected from the 
group consisting of methyl; deuteromethyl (CD3); tritiom-
50 ethyl (CT 3 ); ethyl; propyl; isopropyl; C4 -C7 straight chain or 
branched alkyl; C3 -C6 cycloalkyl; C4 -C7 alkenyl; benzyl; 
phenylethyl; amino; N-methylamino; N,N-dimethylamino; 
carboxylate; methylcarboxylate; ethylcarboxylate; propyl-
carboxylate; isopropylcarboxylate; carboxaldehyde; 
55 acetoxy; propionyloxy; isopropionyloxy; cyano; aminom-
ethyl; N-methylaminomethyl; N,N-dimethylaminomethyl; 
carboxamide; N-methylcarboxamide; N,N-dimethylcarbox-
amide; acetyl; propionyl; formyl; benzoyl sulfate; phenyl; 
methylsulfate; hydroxyl; methoxy; ethoxy; propoxy; iso-
60 propoxy; thiol; methylthio; ethylthio; propiothiol; fluoro; 
chloro; bromo; iodo; trifluoromethyl; vinyl; ally!; propargyl; 
nitro; carbamoyl; ureido; azido; isocyanate; thioisocyanate; 
hydroxylamino; nitroso; a saturated or unsaturated hydro-
carbon ring; a nitrogen-containing heterocyclic moiety; an 
65 oxygen-containing heterocyclic moiety; a sulfur-containing 
heterocyclic moiety; a selenium-containing heterocyclic 
moiety; a mixed heterocyclic moiety containing at least two 
US 10,668,030 B2 
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atoms selected from the group consisting of nitrogen, oxy-
gen and sulfur; and ortho, meta or para-substituted benzene; 
R3 is methyl, ethyl, propyl, isopropyl, hydroxymethyl, 
2-hydroxyethyl, 1-hyhydroxyethyl, methoxymethyl, 
2-methoxyethyl, 1-methoxyethyl, aminomethyl, 2-amino- 5 
ethyl, 1-aminoethyl, N-methylaminomethyl, 2-N-methyl-
aminoethy 1, 1-N-methy laminoethyl, N,N-dimethy laminom-
ethy l, 2-N,N-dimethylaminoethyl, or 1-N,N-
dimethylaminoethyl group; and 
R4 is a hydrogen atom or a methyl, ethyl, propyl, or 10 
isopropyl group; or 
an enantiomer; racemate; or pharmaceutically acceptable 
salt thereof. 
4 
hydrogen atom; or an enantiomer; racemate; or pharmaceu-
tically acceptable salt thereof. 
Yet another embodiment of the invention is a compound 
of formula (I), wherein mis 1; n is 2; R1 is an unsubstituted 
phenyl group; R2 is a phenyl group substituted with a 
methoxy group; R3 is methyl; and R4 is a hydrogen atom; or 
an enantiomer; racemate; or pharmaceutically acceptable 
salt thereof. 
Compounds of formula (I) include the following com-
pounds: 
1. m=l, n=l, R1=Ph, R2 =Ph, R3 =Me, R4 =H 
2. m=l, n=l, R1=Ph, R2 =Ph, R3 =Me, R4 =CH3 
3. m=l, n=l, R1=4-BrPh, R2 =Ph, R3=Me, R4 =H 
4. m=l, n=2, R1=Ph, R2 =Ph, R3 =Me, R4 =H 
5. R-, m=l, n=2, R1=Ph, R2=Ph, R3 =Me, R4 =H 
A further embodiment of the invention is a compound of 
formula (I), wherein: m is 1 or 2; and n is an integer from 
1 to 5; or an enantiomer; racemate; or pharmaceutically 
acceptable salt thereof. 
15 6. S-, m=l, n=2, R1=Ph, R2 =Ph, R3 =Me, R4 =H 
An further embodiment of the invention is a compound of 
formula (I), wherein: m is 1 or 2; and n is an integer from 
1 to 5; R3 is methyl, ethyl, propyl, or isopropyl; and R4 is a 
hydrogen atom or a methyl, ethyl, propyl, or isopropyl 
group; or an enantiomer; racemate; or pharmaceutically 
acceptable salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: m is 1 or 2; and n is an integer from 
1 to 5; wherein R3 is methyl; and R4 is a hydrogen atom or 
a methyl group; or an enantiomer; racemate; or pharmaceu-
tically acceptable salt thereof. 
Another embodiment of the invention is a compound of 
formula (I), wherein m is 1; n is 1; R1 and R2 are each 
independently a phenyl group, wherein R1 and R2 are each 
independently unsubstituted or substituted by one or more 
substituents selected from the group consisting of benzyl; 
amino; hydroxyl; methoxy; fluoro; bromo; and nitroso; R3 is 
methyl; and R4 is a hydrogen atom or a methyl group; or an 
enantiomer; racemate; or pharmaceutically acceptable salt 
thereof. 
Another embodiment of the invention is a compound of 
formula (I), wherein m is 1; n is 2; R1 and R2 are each 
independently a phenyl group, wherein R1 and R2 are each 
independently unsubstituted or substituted by one or more 
substituents selected from the group consisting of benzyl; 
amino; hydroxyl; methoxy; fluoro; bromo; and nitroso; R3 is 
methyl; and R4 is a hydrogen atom or a methyl group; or an 
enantiomer; racemate; or pharmaceutically acceptable salt 
thereof. 
Another embodiment of the invention is a compound of 
formula (I), wherein m is 2; n is 1; R1 and R2 are each 
independently a phenyl group, wherein R1 and R2 are each 
independently unsubstituted or substituted by one or more 
substituents selected from the group consisting of methoxy 
and bromo; R3 is methyl; and R4 is a hydrogen atom; or an 
enantiomer; racemate; or pharmaceutically acceptable salt 
thereof. 
Yet another embodiment of the invention is a compound 
of formula (I), wherein m is 2; n is 2; R1 and R2 are each 
independently a phenyl group, wherein R1 and R2 are each 
independently unsubstituted or substituted by one or more 
methoxy groups; R3 is methyl; and R4 is a hydrogen atom or 
a methyl group; or an enantiomer; racemate; or pharmaceu-
tically acceptable salt thereof. 
Yet another embodiment of the invention is a compound 
of formula (I), wherein m is 1; n is an integer from 3 to 5; 
R1 and R2 are each independently a phenyl group, wherein 
7. m=l, n=2, R1=Ph, R2 =Ph, R3 =Me, R4 =CH3 
8. m=l, n=2, R1=Ph, R2 =4-MeOPh, R3 =Me, R4 =H 
9. R-, m=l, n=2, R1=Ph, R2=4-MeOPh, R3=Me, R4 =H 
10. S-, m=l, n=2, R1=Ph, R2 =4-MeOPh, R3 =Me, R4 =H 
20 11. m=l, n=2, R1=4-BrPh, R2 =Ph, R3 =Me, R4 =H 
12. R-, m=l, n=2, R1=4-BrPh, R2=Ph, R3=Me, R4 =H 
13. S-, m=l, n=2, R1=4-BrPh, R2=Ph, R3=Me, R4 =H 
14. m=l, n=3, R1=4-BrPh, R2=Ph, R3=Me, R4 =H 
15. m=l, n=3, R1=Ph, R2 =Ph, R3 =Me, R4 =H 
25 16. m=l, n=2, R1=4-BrPh, R2=4-MeOPh, R3=Me, R4 =H 
17. m=l, n=4, R1=Ph, R2 =Ph, R3 =Me, R4 =H 
18. m=l, n=5, R1=Ph, R2 =Ph, R2 =Me, R4 =H 
19. m=l n=l, R1=Ph, R2=PhO, R3=Me, R4 =H 
20. m=l, n=l, R1=4-BrPh, R2=PhO, R3=Me, R4 =H 
30 
21. m=l, n=l, R1=Ph, R2 =4-OHPh, R3 =Me, R4 =H 
22. m=l, n=l, R1=Ph, R2 =3,4-diBnOPh, R3 =Me, R4 =H 
23. m=l, n=l, R1=Ph, R2 =3,4-diOHPh, R3 =Me, R4 =H 
24. m=l, n=l, R1=4-MeOPh, R2 =Ph, R3 =Me, R4 =H 
25. m=l, n=l, R1=4-MeOPh, R2 =Ph, R3 =Me, R4 =CH3 
26. m=l, n=2, R1=4-MeOPh, R2 =Ph, R3 =Me, R4 =H 
35 27. R-, m=l, n=2, R1=4-MeOPh, R2 =Ph, R3 =Me, R4 =H 
28. S-, m=l, n=2, R1=4-MeOPh, R2 =Ph, R3 =Me, R4 =H 
29. m=l, n=2, R1=4-MeOPh, R2 =4-MeOPh, R3 =Me, R4 =H 
30. m=l, n=2, R1=4-MeOPh, R2 =Ph, R3 =Me, R4 =CH3 
31. m=2, n=l, R1=4-MeOPh, R2 =Ph, R3 =Me, R4 =H 
40 32. m=2, n=2, R1=4-MeOPh, R2 =Ph, R3 =Me, R4 =H 
33. m=2, n=l, R1=4-MeOPh, R2 =4-MeOPh, R3 =Me, R4 =H 
34. m=2, n=l, R1=4-MeOPh, R2 =4-BrPh, R3=Me, R4 =H 
35. m=l, n=l, R1=4-OHPh, R2 =Ph, R3 =Me, R4 =H 
36. m=l, n=2, R1=4-OHPh, R2 =4-MeOPh, R3 =Me, R4 =H 
45 37. m=l, n=2, R1=4-OHPh, R2 =Ph, R3 =Me, R4 =H 
38. m=l, n=l, R1=4-FPh, R2 =Ph, R3 =Me, R4 =H 
39. m=l, n=2, R1=4-FPh, R2 =Ph, R3 =Me, R4 =H 
40. m=l, n=2, R1=4-FPh, R2 =4-MeOPh, R3 =Me, R4 =H 
41. m=l, n=l, R1=4-NO2 Ph, R2=Ph, R3=Me, R4 =H 
50 42. m=l, n=2, R1=4-NO2 Ph, R2=Ph, R3=Me, R4 =H 
43. m=l, n=2, R1=4-NO2 Ph, R2 =4-MeOPh, R3=Me, R4 =H 
44. m=l, n=l, R1=4-NH2 Ph, R2=Ph, R3=Me, R4 =H 
45. m=l, n=2, R1=4-NH2 Ph, R2=Ph, R3=Me, R4 =H 
46. m=l, n=2, R1=3,4-diMeOPh, R2 =Ph, R3 =Me, R4 =H 
55 47. m=l, n=3, R1=3,4-diMeOPh, R2 =Ph, R3 =Me, R4 =H 
48. m=2, n=l, R1=Ph, R2 =Ph, R3 =Me, R4 =H 
49. m=2, n=l, R1=Ph, R2 =Ph, R3 =Me, R4 =H 
50. m=2, n=2, R1 =Ph, R2 =Ph, R3 =Me, R4 =H 
51. m=2, n=2, R1=Ph, R2 =Ph, R3 =Me, R4 =CH3 
60 52. m=2, n=2, R1=Ph, R2 =4-MeOPh, R3 =Me, R4 =H 
53. m=2, n=2, R1=4-MeOPh, R2=4-MeOPh, R3 =Me, R4 =H. 
Definitions 
R1 and R2 are each independently unsubstituted or substi- 65 
tuted by one or more substituents selected from the group 
consisting of methoxy and bromo; R3 is methyl; and R4 is a 
The term "aryl" refers to aromatic groups having 6 to 24 
carbon atoms, and "substituted aryl" refers to aryl groups 
further bearing one or more substituents. 
US 10,668,030 B2 
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The term "alkyl" refers to straight or branched chain alkyl 
radicals having 1 to 19 carbon atoms, and "substituted alkyl" 
refers to alkyl radicals further bearing one or more substitu-
ents. 
The term "lower alkyl" refers to straight or branched 
chain alkyl radicals having in the range of 1 to 4 carbon 
atoms. 
The term "cycloalkyl" refers to cyclic ring-containing 
moieties containing 3 to 8 carbon atoms, and "substituted 
cycloalkyl" refers to cycloalkyl moieties further bearing one 
or more substituents. 
The term "alkenyl" refers to straight or branched chain 
hydrocarbyl groups having at least one carbon-carbon 
double bond and having 2 to 19 carbon atoms, and "substi-
tuted alkenyl" refers to alkenyl groups further bearing one or 
more substituents. 
The term "heterocyclic" refers to cyclic moieties contain-
ing one or more heteroatoms as part of the ring structure and 
having 3 to 24 carbon atoms, and "substituted heterocyclic" 
refers to heterocyclic moieties further bearing one or more 
substituents. 
Pharmaceutically acceptable salts include c1-, Br-, 1-, 
No2 -, HSO4 -, SO4 -, HPO4 -, Po/-, ethanesulfonate, tri-
fluromethane sulfate, p-toluenesulfonate, benzenesulfonate, 
salicylate, proprionate, ascorbate, aspartate, fumarate, 
galactarate, maleate, citrate, glutamate, glycolate, lactate, 
malate, maleate, tartrate, oxalate, succinate, or similar acid 
addition salts. The above salt forms may be in some cases 
hydrates or solvates with alcohols and other solvents. 
Pharmaceutical Compositions 
6 
The compounds disclosed herein can be administered 
alone, combined with a pharmaceutically acceptable excipi-
ent, or co-administered with a second drug. Co-administra-
tion may provide a similar or synergistic effect. A compound 
5 of formula (I) or a pharmaceutically acceptable salt thereof 
can be administered subcutaneously, intramuscularly, intra-
venously, transdermally, orally, intranasally, intrapulmonary, 
or rectally. 
The dose of the pharmaceutical composition of the pres-
10 ent invention is appropriately selected in accordance with 
dosage regimen, age, sex and the other conditions of a 
patient. The amount to be administered depends to some 
extent on the lipophilicity of the specific compound selected, 
since it is expected that this property of the compound will 
cause it to partition into fat deposits of the subject. The 
15 precise amount to be administered can be determined by the 
skilled practitioner in view of desired dosages, side effects 
and medical history of the patient and the like. 
The pharmaceutical composition may comprise a com-
pound of formula (I), or an enantiomer or racemate thereof, 
20 or pharmaceutically acceptable salt thereof, and a pharma-
ceutically acceptable additive or a pharmaceutically accept-
able excipient. 
Treatment of Drug Abuse 
VMAT2 is considered as a valid target for the develop-
25 ment of treatments for the abuse of drugs, including, for 
example, methamphetamine (METH), amphetamine, 
cocaine, methylphenidate, and opiate abuse. For example, 
METH decreases vesicular DA sequestration by inhibiting 
vesicular uptake through VMAT2 (IC50=14.9 µM) and by 
30 
diffusing across the vesicular membranes to decrease the pH 
gradient, resulting in the loss of free energy needed for 
monoamine transport. 
Also disclosed herein are pharmaceutical compositions 
comprising a compound of formula (I) and pharmaceutically 
acceptable excipients. For example, the pharmaceutical 
35 
composition may include a pharmaceutically acceptable 
additive, such as a stabilizer, buffer, salt, preservative, filler, 
flavor enhancer and the like, as known to those skilled in the 
art. Representative buffers include phosphates, carbonates, 
and citrates. Exemplary preservatives include EDTA, 40 
EGTA, BHA, and BHT. 
Lobelane competitively inhibits [3H]DA uptake into rat 
brain vesicles via interaction with VMAT2 (K,=45 nM), 
decreases METH-evoked DA overflow from rat striatal 
slices, and decreases METH self-administration, but does 
not act as a psychostimulant, suggesting that it has potential 
as a novel treatment for METH abuse. Nor-Lobelane (K1 =44 
nM) is equipotent with lobelane at VMAT2 in inhibiting 
[
3 H]DA uptake. 
METH can be considered as a structural fragment of 
lobelane/nor-lobelane, and introducing bulky substituents 
onto the N-atom of METH afforded compounds with 
increased inhibitory potency at VMAT2, reduced the psy-
chostimulant effects of METH, diminishing its abuse poten-
The pharmaceutical composition disclosed herein may be 
administered by inhalation (i.e., intranasally as an aerosol or 
nasal formulation); topically (i.e., in the form of an oint-
ment, cream or lotion); orally (i.e., in solid or liquid form 
(tablet, capsule, gel cap, time release capsule, powder, 
solution, or suspension in aqueous or non-aqueous liquid); 
intravenously as an infusion or injection (i.e., as a solution, 
suspension or emulsion in a pharmaceutically acceptable 
carrier); or subcutaneously as an infusion or injection (i.e., 
as a solution, suspension or emulsion in a pharmaceutically 
acceptable carrier) or as a depot formulation; transdermally 
(e.g., via a transdermal patch), or rectally (e.g., as a sup-
45 tial. Importantly, these new analogs did not increase loco-
motor activity in rats, indicating they do not act as 
psychostimulants. Lee, N.-R. et al., Drug and Alcohol 
Dependence, "Enantiomers of (±)GZ-888 potently and 
selectively inhibit vesicular monoamine transporter-2 func-




There is no limitation in the route of administration or 
dosage form, and the composition may be administered in 
accordance with specific form of the preparation, age, sex 
and the other conditions of a patient, severity of disease, etc. 
For example, in the case of tablet, pill, solution, suspension, 60 
emulsion, granule and capsule, the composition is orally 
administered. In the case of injection, the composition is 
intravenously administered alone or in a mixture with con-
ventional replacement fluid such as glucose and amino 
acids, and if necessary, and the preparation alone may be 65 
also administered intramuscularly, intracutaneously, subcu-
taneously or interperitoneally. 
METH 
n 
R ~ CH3, Lobelane 
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Treatment of a Disease or Pathology of the Central Nervous 
System or an Eating Disorder 
8 
Modulation of VMAT2 has potential as a therapeutic for 
central nervous system diseases or pathologies. Thus, 
VMAT2 is a target for the development of treatments for a 5 
disease or pathology of the central nervous system, includ-
ing, for example, cognitive disorders, brain trauma, memory 
loss, psychosis, sleep disorders, obsessive compulsive dis-
orders, panic disorders, myasthenia gravis, Parkinson's dis-
ease, Alzheimer's disease, schizophrenia, Tourette's syn- 10 
drome, Huntington's disease, attention deficit hyperactivity 
disorder, hyperkinetic syndrome, chronic nervous exhaus-
tion, narcolepsy, pain, motion sickness, and/or depression. 
the drug which the individual is using and/or dependent 
upon may be amphetamine, methamphetamine, and other 
drugs that release dopamine. 
EXAMPLES 
A series of VMAT2 inhibitors were synthesized and 
evaluated for their activity at VMAT2, dopamine transport-
ers (DAT), and serotonin transporters (SERT) using rat 
striatum, hERG channels expressed by HEK-293 cells, and 
for their effect on METH-stimulated locomotor activity in 
rats. Compounds of the invention exhibited affinity at 
VMAT2 as well as selectivity at VMAT2 over hERG, DAT, 
and SERT. Further, a significant reduction of METH-stimu-
lated locomotor activity was observed after administration 
of the compounds. 
VMAT2 is also a target for the development of treatments 
15 
for eating disorders, including, for example, obesity. Com-
pulsive eating is linked to addiction-like neuroadaptive 
responses in brain reward circuits. Johnson, P. M. et al., 
"Dopamine D2 receptors in addiction-like reward dysfunc-
tion and compulsive eating in obese rats," Nature Neuro- 20 
science, 2010, 13, 635-641. Modulation of VMAT2 may 
lead to reduced reward responses, diminishing overeating. 
Example 1 
Synthesis of compound 10. (S)-3-(4-methoxyphe-
nyl)-N-(1-phenylpropan-2-yl)propan-l-amine 
A more preferred embodiment of the invention is a 
compound of formula (I), wherein the compound is 3-( 4-
methoxypheny 1)-N-( l -phenylpropan-2-y l)propan-1-amine 25 
or an enantiomer; racemate; or pharmaceutically acceptable 
salt thereof. 
To a solution of phenyllithium (50 mL, 1.8 Min dibutyl 
ether) in THF (50 mL) was added (R)-propylene oxide (5 g) 
dropwise at - 78° C. The resulting mixture was stirred at the 
same temperature for 1 hr before warmed to room tempera-
ture. After stirred at room temperature overnight, the reac-
tion was quenched by adding saturated NH4Cl aqueous 
solution. The aqueous phase was extracted with ethyl acetate 
An even more preferred embodiment of the invention is a 
compound of formula (I), wherein the compound is (S)-3-
( 4-methoxypheny I )-N-(1-pheny lpropan-2-y l)propan-1-
amine hydrochloride. 
A more preferred embodiment of the invention is a 
pharmaceutical composition comprising 3-( 4-methoxyphe-
nyl)-N-(l-phenylpropan-2-yl)propan-1-amine or an 
enantiomer; racemate; or pharmaceutically acceptable salt 
thereof and a pharmaceutically acceptable additive or a 
pharmaceutically acceptable excipient. An even more pre-
ferred embodiment of the invention is a pharmaceutical 
composition comprising (S)-3-( 4-methoxyphenyl)-N-(l-
phenylpropan-2-yl)propan-l-amine hydrochloride and a 
pharmaceutically acceptable additive or a pharmaceutically 
acceptable excipient. 
Another preferred embodiment of the invention is a 
method of treating a disease or pathology of the central 
nervous system or an eating disorder in an individual in need 
thereof, wherein the method comprises the step of admin-
istering to the individual a compound of formula (I) or a 
pharmaceutically acceptable salt thereof. 
The compounds of the present invention may be used in 
a method of treating a disease or pathology of the central 
nervous system, wherein the disease may be cognitive 
disorders, brain trauma, memory loss, psychosis, sleep dis-
orders, obsessive compulsive disorders, panic disorders, 
myasthenia gravis, Parkinson's disease, Alzheimer's dis-
ease, schizophrenia, Tourette's syndrome, Huntington's dis-
ease, attention deficit hyperactivity disorder, hyperkinetic 
syndrome, chronic nervous exhaustion, narcolepsy, pain, 
motion sickness, and/or depression. 
The compounds of the present invention may also be used 
in a method of treating an eating disorder. The eating 
disorder may be obesity. 
The compounds of the present invention may be used in 
a method of treating substance use disorder, drug depen-
dence/abuse or withdrawal from drug dependence/abuse in 
an individual in need thereof. Substance use disorder and 
drug dependence/abuse includes dependence/abuse of psy-
chostimulants or drugs that release dopamine. For example, 
30 (3x50 mL) and the combined organic layers were washed 
with brine (100 mL), dried over anhydrous Na2 SO4 , filtered 
and concentrated under reduced pressure. The crude product 
was chromatographed on silica (hexanes/ethyl acetate 10:1 
to 3:1) to afford (R)-1-phenylpropan-2-ol (10.4 g) as a 
35 colorless oil. 
To a solution of (R)-1-phenylpropan-2-ol (4.16 g, 30.50 
mmol) and triethylamine (7.72 g, 10.64 mL, 76.27 mmol) in 
dichloromethane (100 mL) was added methanesulfonyl 
chloride (4.54 gm, 3.07 mL, 39.65 mmol) dropwise at 0° C. 
40 The resulting mixture was stirred at 0° C. for 15 min. 
Dichloromethane (100 mL) was added to the mixture and 
then washed with water (2x150 mL). The organic layer was 
dried over anhydrous Na2 SO4 , filtered and concentrated 
under reduced pressure. The resulting light yellow oil was 
45 mixed with sodium azide (5.95 g, 91.5 mmol) in DIME (40 
mL) and heated at 55° C. for 3 hrs. The reaction mixture was 
diluted with diethyl ether (150 mL) and washed with water 
(2x100 mL) and brine (100 mL). The organic layer was 
dried over anhydrous Na2 SO4 , filtered and concentrated 
50 under reduced pressure. The crude product was chromato-
graphed on silica (hexanes/ethyl acetate 50:1 to 20:1) to 
afford (S)-(2-azidopropyl)benzene ( 4.38 g) as a colorless oil. 
To a solution of (S)-(2-azidopropyl)benzene ( 4.0 g, 24.81 
mmol) in THF (90 mL) and water (10 mL) was added 
55 triphenylphosphine (9.11 g, 34.74 mmol) at room tempera-
ture. The resulting mixture was stirred for 18 hrs and water 
(50 mL) was added. The resulting mixture was treated with 
HCI (1.0 M) to pH-1 and the aqueous phase was extracted 
with diethyl ether (3x100 mL) and dichloromethane (2x100 
60 mL). NaOH (15%) was added dropwise to the aqueous 
phase to adjust the pH to about 11 and extracted with 
dichloromethane (5x60 mL). The combined organic layers 
were dried over anhydrous Na2 SO4 , filtered and concen-
trated under reduced pressure to afford (S)-l-phenylpropan-
65 2-amine as a colorless oil. The crude amino product (3.03 g, 
22.41 mmol) was mixed with 3-(4-methoxyphenyl)pro-
panoic acid (4.44 g, 24.65 mmol), and HOBt (3.63 g, 26.89 
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mmol) in dichloromethane (60 mL) at room temperature. 
Triethylamine (5.67 g, 56.03 mmol) was added followed by 
EDCI (5.15 g, 26.89 mmol). The resulting mixture was 
stirred overnight. The reaction mixture was diluted with 
dichloromethane (100 mL) and washed with water (3x50 5 
mL), and brine (50 mL). The organic layer was dried over 
anhydrous Na2 SO4 , filtered and concentrated under reduced 
pressure. The crude product was chromatographed on silica 
( dichloromethane/ethyl acetate 10: 1) to afford (S)-3-( 4-
10 methoxypheny 1)-N-( l -phenylpropan-2-y l)propanamide 
(6.18 g) as a white solid. (S)-3-(4-Methoxyphenyl)-N-(1-
phenylpropan-2-yl)propanamide (5.0 g, 16.81 mmol) in 
THF was cooled to 0° C. LAH (60 mL, 1.0 Min THF) was 
added dropwise and the resulted reaction mixture was heated 
15 
at reflux for 6 hrs. After cooled to 0° C., water (2.28 mL) was 
carefully added, followed by NaOH (15%, 2.28 mL) and 
water (6.84 mL). The resulted mixture was warmed to room 
temperature and stirred for 2 hrs. Filtered over celite and 
washed with ethyl acetate. The filtrate was concentrated 20 
under reduced pressure and the crude product was chro-
matographed on silica ( dichloromethane/methanol 30: 1 to 




3 H]Dopamine ([3H]DA) Uptake Assay, Vesicular 
Preparation 
Inhibition of [3 H]DA uptake was conducted using isolated 
synaptic vesicle preparations (Teng et al., 1997). Briefly, rat 
striata were homogenized with 10 up-and-down strokes of a 
Teflon pestle homogenizer (clearance-0.003") in 14 ml of 
0.32 M sucrose solution. Homogenates were centrifuged 
(2,000 g for 10 min at 4 ° C. ), and then the supernatants were 
centrifuged (10,000 g for 30 min at 4° C.). Pellets were 
resuspended in 2 ml of 0.32 M sucrose solution and sub-
jected to osmotic shock by adding 7 ml of ice-cold MilliQ 
water to the preparation. After 1 min, osmolarity was 
restored by adding 900 µI of0.25 M HEPES buffer and 900 
µI of 1.0 M potassium tartrate solution. Samples were 
centrifuged (20,000 g for 20 min at 4° C.), and the super-
natants were centrifuged (55,000 g for 1 hr at 4° C.), 
followed by addition of 100 µI of 10 mM MgSO4 , 100 µI of 
0.25 M HEPES and 100 µI of 1.0 M potassium tartrate 
solution prior to the final centrifugation (100,000 g for 45 
min at 4° C.). Final pellets were resuspended in 2.4 ml of 
assay buffer (25 mM HEPES, 100 mM potassium tartrate, 50 
Example 2 
[
3 H]Dihydrotetrabenazine ([3H]DTBZ) Binding 
Assay, Vesicular Preparation 
Synaptic vesicles were prepared from rat brain using a 
modification of a previously described procedure (Teng et 
al., 1998). Briefly, fresh whole brain (excluding cerebellum) 
was homogenized using a Teflon pestle (clearance 0.003 
inches) with 7 vertical strokes at 800 rpm in 20 vol of 
ice-cold 0.32 M sucrose and centrifuged at 1000 g for 12 min 
25 µM EGTA, 100 µM EDTA, 1.7 mM ascorbic acid, 2 mM 
ATP-Mg2+, pH 7.4). Aliquots of the vesicular suspension 
(100 µ!) were added to tubes containing assay buffer, various 
concentrations of compound (0.1 nM-10 mM) and 0.1 µM 
[
3 H]DA in a final volume of 500 µ!, and incubated at 37° C. 
30 for 8 min. Nonspecific uptake was determined in the pres-
ence of the standard compound, Ro4-1284 (10 µM). Reac-
tions were terminated by filtration, and radioactivity retained 
by the filters was determined by liquid scintillation spec-
trometry (Tri-Carb 2100TR liquid scintillation analyzer; 
at 4° C. The resulting supernatant (S 1) was then centrifuged 
35 PerkinElmer Life and Analytical Sciences, Boston, Mass.). 
at 22,000 g for 10 min at 4° C. The synaptosomal pellets (P2 ) 
were homogenized in 18 mL of ice-cold Milli-Q water and 
exposed for 5 min for lysing synaptosomes. Osmolarity was 
restored by addition of 2 mL of 25 mM HEPES with 100 40 
mM dipotassium tartrate (pH 7 .5). Samples were centrifuged 
at 20,000 g for 20 min at 4° C. to remove lysed synapto-
somal membranes. MgSO4 (1 mM) was added to the super-
natant (S3), and was centrifuged at 100,000 g for 45 min at 
4 ° C. The final vesicular pellets (P 4 ) were resuspended in 45 
ice-cold assay buffer (see below) providing-15 µg protein/ 
100 µL, determined by the method of Bradford (1976) using 
bovine serum albumin as a the standard. Aliquot parts (100 
µL) of suspension of vesicle membrane protein were incu-
bated in assay buffer (25 mM HEPES, 100 mM dipotassium 50 
tartrate, 5 mM MgSO4 , 0.1 mM EDTA and 0.05 mM EGTA, 
pH 7.5, at 25° C.) in the presence of3 nM [3 H]DTBZ and 
at least 7 concentrations (1 nM-1 mM) of compound for 1 hr 
at room temperature. Nonspecific binding was determined in 
the presence of 20 µM tetrabenazine, a standard compound. 55 
Assays were performed in duplicate using a 96-well plate 
format. Reactions were terminated by filtration of samples 
on a Unifilter-96 GF/B filter plates (presoaked in 0.5% 
polyethylenimine), using a FilterMate harvester (Packard 
BioScience Co., Meriden, Conn.). After washing 5 times 60 
with 350 µL of the ice-cold wash buffer (25 mM HEPES, 
100 mM dipotassium tartrate, 5 mM MgSO4 and 10 mM 
NaCl, pH 7.5), filter plates were dried, sealed and each well 
filled with 40 µL Packard's MicroScint 20 cocktail. Bound 
[
3H]DTBZ was measured using a Packard TopCount NXT 65 




3 H]Dofetilide Binding Assay, HEK-293 Cell 
Membrane Preparation 
[
3H]Dofetilide binding assays were conducted using com-
mercially available HEK-293 cell membranes which stably 
express the hERG charmel. Membranes were suspended in 
assay buffer (50 mM Tris, 10 mM KC!, 1 mM MgCl2 , pH 
7.4) prior to the experiment. Assays were performed in 
duplicate in a total volume of 250 µL. Aliquots of the 
HEK-293 cell membrane suspension which contained 5 µg 
membrane protein were added to tubes containing assay 
buffer, 5 nM [3H]dofetilide and a range of concentrations of 
analog (10 nM-100 µM). Nonspecific binding was deter-
mined in the presence of amitriptyline (1 mM). Samples 
were incubated for 1 hr. at 24° C., followed by rapid 
filtration. Radioactivity retained by the filters was deter-
mined by liquid scintillation spectrometry as described 
above for the [3H]DA uptake assay. The affinity for the 
[
3 H]dofetilide binding site on the hERG channel expressed 
in the HEK-293 cellular membrane was determined from the 
analog concentration response curves. 
Example 5 
[
3 H]DA and [3H]5-HT Uptake Assay, Synaptosomal 
Preparation 
[
3H]DA and [3 H]5-HT uptake into striatal synaptosomes 
was determined to evaluate compound inhibition of the 
US 10,668,030 B2 
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dopamine transporter (DAT) and the serotonin transporter 
(SERT), respectively. Striata from individual rats were 
homogenized in ice-cold sucrose solution containing 5 mM 
NaHCO3 (pH 7.4), with 16 up-and-down strokes ofa Teflon 
pestle homogenizer (clearance,.,0.003"). Homogenates were 5 
centrifuged at 2000 g for 10 min at 4 ° C., and resulting 
supematants were centrifuged at 20,000 g for 17 min at 4° 
C. Pellets were resuspended in 2.4 mL (for DAT assays) or 
1.5 mL (for SERT assays) of assay buffer (125 mM NaCl, 5 
mM KC!, 1.5 mM MgSO4 , 1.25 mM CaCl2 , 1.5 mM 
10 
KH2 PO4 , 10 mM alpha-D-glucose, 25 mM HEPES, 0.1 mM 
EDTA, 0.1 mM pargyline, 0.1 mM ascorbic acid, saturated 
with 95% 0i5% CO2 , pH 7.4). Assays were performed in 
duplicate in a total volume of 500 µL (for DAT assays) or 
15 
250 µL (for SERT assays). Aliquots of the synaptosomal 
suspension (25 µL for DAT, 50 µL for SERT) were added to 
tubes containing assay buffer and various concentrations of 




Nonspecific uptake was determined in the presence of 
nomifensine (10 µM) for DAT assays or fluoxetine (10 µM) 
for SERT assays. GBR-12935 (100 nM) was included in the 
assay buffer for the SERT assay to maximally inhibit [3 H] 
5-HT uptake through DAT and isolate uptake to SERT. 
Samples were placed on ice, and 50 µL of 0.1 µM [3 H]DA 
(for DAT assays) or 25 µL of 0.1 µM [3H]5-HT (for SERT 
assays) was added to each tube, and incubated for 10 min at 
34° C. Reactions were terminated by addition of 3 mL of 
ice-cold assay buffer and subsequent filtration and radioac-
tivity retained by the filters was determined by liquid 
scintillation spectrometry (Tri-Carb 2100TR liquid scintil-
lation analyzer; PerkinElmer Life and Analytical Sciences, 
Boston, Mass.). 
Exemplary compounds 1-53 were tested in [3 H]dihydro-
tetrabenazine ([3H]DTBZ) binding assay according to 
Example 2 and the [3H]dopamine ([3 H]DA) uptake assay 
according to Example 3. The results of these assays are set 
forth in Table 1. 
TABLE 1 
[
3 H]DTBZ binding [3H]DA Uptake (Ki) 
(Ki) VMAT2 (µM) VMAT2 (µM) 
7.70 ± 1.25 0.063 ± 0.005 
vYN::U HCl I # 
2 CH3 
I 
7.53 ± 2.16 0.51 ± 0.10 
vYN::U HCl I # 
3 H 1.23 ± 0.13 0.033 ± 0.007 
Br 
,OIN::U 
HCl I # 
4 
' ~~ °'He, 




0.91 ± 0.59 0.006 ± 0.001 
6 
' ij~ °'He, 
0.75 ± 0.14 0.065 ± 0.004 
7 
I~ VIN ' 
HCl 
1.56 ± 0.47 0.096 ± 0.010 




3H]DTBZ binding [3 H]DA Uptake (Ki) 
Compound Structure (Ki) VMAT2 (µM) VMAT2 (µM) 
8 ~o, 2.2 ± 0.11 0.014 ± 0.003 
~ vYHC, 
9 ~o, 0.0087 ± 0.0065 
()i""ij 
HCl 
















0.032 ± 0.004 
f)!Hc, 
Br 
14 H 0.081 ± 0.016 0.003 ± 0.0003 f)IN~ 
HCl I ,# 
Br 
15 H 0.19 ± 0.020 0.003 ± 0.002 vYN~ HCl I ,# 








3H]DTBZ binding [3 H]DA Uptake (Ki) 
Compound Structure (Ki) VMAT2 (µM) VMAT2 (µM) 
17 
'¾ ~~ 
0.63 0.014 ± 0.001 
vYHc, 













21 H 1.5 ± 0.2 0.12 ± 0.01 vYN~ 
HCl I # OH 
22 H 2.0 ± 0.1 0.12 ± 0.001 vYN~Ofu 
HCl I # 
OBn 
23 H 3.4 ± 0.6 0.092 ± 0.017 vYN~OH 
HCl I # OH 
24 H 3.77 ± 0.99 0.074 ± 0.002 ,DIN::U '----o HCl I # 
25 CH3 
I 
11.9 ± 1.84 0.46 ± 0.075 
,DIN::U 
'----o HCl I # 
26 
'¾ ij~ 
1.27 ± 0.09 0.022 ± 0.003 
,O,DIHC, 




3H]DTBZ binding [3 H]DA Uptake (Ki) 
Compound Structure (Ki) VMAT2 (µM) VMAT2 (µM) 
27 
~ 






0.020 ± 0.001 
,O,DIHC, 





7.11 ± 0.82 0.27 ± 0.038 
,DIN ~ 
'-.,.O HCl 
31 /0 2.4 ± 0.1 0.062 ± 0.029 
H N~ 
HCl I # 
32 /0 
ij~ 
4.7 ± 0.4 0.030 ± 0.002 
HCl 
33 /0 1.5 ± 0.2 0.060 ± 0.007 
H N~ 
HCl I # 0/ 
34 /0 0.87 ± 0.03 0.010 ± 0.004 
H N~ 
HCl I # 
Br 
35 H 2.6 ± 0.4 0.047 ± 0.006 
,DIN~ 
HO HCl I # 




3H]DTBZ binding [3 H]DA Uptake (Ki) 
Compound Structure (Ki) VMAT2 (µM) VMAT2 (µM) 
36 
~o'-





0.82 ± 0.27 0.033 ± 0.008 
,O!Hc, 
HO 
38 H 2.5 ± 1.6 0.069 ± 0.009 
,DIN:V 
F HCl I # 
39 
'¾ ij~ 




1.7 ± 0.4 0.017 ± 0.003 
~ 
,,DI He, 
41 H 5.1 ± 1.2 0.060 ± 0.007 
O2N 
,,()"''(:-V HCl I # 
42 
'¾ ij~ 









44 H 17 ± 6.6 0.21 ± 0.08 
H2N 
,OIN:::U 
2HC1 I # 




3H]DTBZ binding [3 H]DA Uptake (Ki) 
Compound Structure (Ki) VMAT2 (µM) VMAT2 (µM) 
45 
~ ~~ 





3.8 ± 0.1 0.14 ± 0.013 
/OX)!~ 
'-.. I # HCl 
0 
47 H 1.1 ± 0.1 0.029 ± 0.011 /OX)IN~ 
'---o I ,-::::; HCI I ,-::::; 
48 "¾ 1.60 ± 0.33 0.050 ± 0.004 
H 
# N~ 
HCl I # 
49 "¾ 29.8 ± 11.2 0.084 ± 0.004 CH3 
I 
# N~ 
HCl I # 
50 "¾ 
ij~ 





17.2 ± 6.33 0.36 ± 0.034 
# N ~ 
HCl 
52 ~o, 3.2 ± 0.1 0.026 ± 0.002 
~ 
HCl 
53 /0 ~o, 1.5 ± 0.7 0.024 ± 0.006 
~ 
HCl 
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As illustrated by Table 1, compounds of the invention 
exhibited high affinity at VMAT2 as well as selectivity at 
VMAT2 over hERG, DAT, and SERT. For example, Com-
pound 9 exhibited a K1 value of 8.71±3.65 at VMAT2, and 
Compound 10 exhibited a K1 value of 25.5±3.57 nM at 5 
VMAT2. Further, both Compound 9 and Compound 10 
exhibited a >30-fold selectivity at VMAT2 over hERG, 
DAT, and SERT. 
The invention claimed is: 
1. A method of treating a substance use disorder of 
methamphetamine, drug dependence/abuse of methamphet-
amine, or withdrawal from drug dependence/abuse of meth-
amphetamine in an individual in need thereof comprising 
administering a compound of formula (I), where the com-
pound of formula (I) is (S)-3-(4-methoxyphenyl)-N-(1-phe-
nylpropan-2-yl)propan-1-amine; (R)-3-( 4-methoxyphenyl)-
N-(l-phenylpropan-2-yl)propan-l-amine; or 
The compounds of the invention were also evaluated for 
their effect on METH-stimulated locomotor activity was 
evaluated in rats. The compounds were observed to exhibit 
a significant reduction of METH-stimulated locomotor 
activity after administration. For example, a significant 
reduction of METH-stimulated locomotor activity was 
observed after administration of Compound 9 (3 mg/kg, s.c.) 
and Compound 10 (17 mg/kg, s.c.). 
The foregoing description and examples have been set 
forth merely to illustrate the invention and are not meant to 
be limiting. Since modifications of the described embodi-
ments incorporating the spirit and the substance of the 
invention may occur to persons skilled in the art, the 
invention should be construed broadly to include all varia-
tions within the scope of the claims and equivalents thereof. 
10 
pharmaceutically acceptable salt thereof. 
2. The method of claim 1, wherein the compound of 
formula (I) is (S)-3-(4-methoxyphenyl)-N-(1-phenylpropan-
2-yl)propan-1-amine hydrochloride. 
3. The method of claim 1, wherein the (S)-3-( 4-methoxy-
phenyl)-N-(l-phenylpropan-2-yl)propan-1-amine; (R)-3-( 4-
15 methoxyphenyl)-N-(l-phenylpropan-2-yl)propan-1-amine; 
or pharmaceutically acceptable salt thereof is present in a 
pharmaceutical composition further comprising a pharma-
ceutically acceptable excipient. 
4. The method of claim 3, wherein the pharmaceutical 
20 con_iposition is administered to the individual by inhalation; 
topically; orally; intravenously as an infusion or injection; or 
subcutaneously as an infusion, injection, or depot formula-
tion; transdermally; or rectally. 
* * * * * 
